What pharmacologic agents can be used to treat insulin resistance in a patient who declines metformin?

Alternative Pharmacologic Agents for Insulin Resistance When Metformin is Refused

If a patient refuses metformin for insulin resistance or type 2 diabetes, select from six alternative first-line options based on patient-specific factors: thiazolidinediones (TZDs), sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, or basal insulin. 1

Patient-Centered Selection Algorithm

When metformin is not an option, the choice of alternative agent should follow this structured approach:

For Patients with Cardiovascular Disease or High CV Risk

• Prioritize SGLT2 inhibitors or GLP-1 receptor agonists with proven cardiovascular benefit as these reduce major adverse cardiovascular events, hospitalization for heart failure, and mortality independent of A1C lowering 1
• These agents should be initiated regardless of baseline A1C and can be used as monotherapy when metformin is refused 1
• GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) reduce A1C by 1.0-2.0% and promote weight loss of 3-5 kg 1
• SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) reduce A1C by 0.5-1.0%, decrease body weight by 1.5-3.5 kg, and lower systolic blood pressure by 3-5 mmHg 1

For Patients with Chronic Kidney Disease

• GLP-1 receptor agonists and SGLT2 inhibitors are preferred as they slow CKD progression and reduce cardiovascular risk 1
• SGLT2 inhibitors can be initiated if eGFR is above 20 mL/min/1.73 m² 1
• GLP-1 receptor agonists maintain efficacy regardless of kidney function with low hypoglycemia risk 1

For Obese or Overweight Patients (Without CV Disease/CKD)

• Thiazolidinediones (pioglitazone) are highly effective for insulin resistance as they activate PPARγ receptors, directly improving peripheral insulin sensitivity 2, 3
• TZDs reduce A1C by approximately 0.7-1.0% when used as monotherapy 1
• Weight gain (1.5-3.5 kg) occurs with TZDs but is associated with decreased insulin resistance, unlike weight gain from other agents 1, 2
• GLP-1 receptor agonists are preferred if weight loss is a priority as they reduce appetite centrally and promote 3-5 kg weight loss 1

For Non-Obese Patients or Those Requiring Rapid Glycemic Control

• Sulfonylureas (glimepiride, gliclazide) are appropriate as they directly stimulate insulin secretion and reduce A1C by 0.7-1.0% 1, 3
• Newer generation sulfonylureas (glimepiride, gliclazide MR) have lower hypoglycemia risk than older agents 1
• Caution: Sulfonylureas cause weight gain and carry hypoglycemia risk, particularly in elderly patients or those with renal impairment 1, 3

For Patients Requiring Moderate Efficacy with Low Hypoglycemia Risk

• DPP-4 inhibitors (sitagliptin, linagliptin, saxagliptin) reduce A1C by 0.7-1.0% without causing hypoglycemia or weight gain when used as monotherapy 1
• These agents are weight-neutral and well-tolerated but less potent than GLP-1 receptor agonists 1

Severe Hyperglycemia Considerations

For patients presenting with A1C ≥10% or fasting glucose ≥300 mg/dL who refuse metformin, initiate basal insulin immediately 1

• Start with 0.1-0.2 units/kg/day of long-acting insulin analog (glargine, detemir, degludec) or NPH insulin 1
• Once glucose toxicity resolves, consider transitioning to oral agents or GLP-1 receptor agonists if appropriate 1

Critical Safety Considerations

Thiazolidinediones

• Contraindicated in heart failure due to fluid retention and edema risk 1, 4
• Monitor for bone fracture risk, particularly in women 4
• Avoid in patients with active liver disease 3

Sulfonylureas

• Avoid chlorpropamide entirely due to prolonged, unpredictable hypoglycemia risk 1
• Reduce doses in elderly patients and those with renal impairment 1, 3
• Higher risk of treatment failure compared to metformin or TZDs 4

SGLT2 Inhibitors

• Rare but serious risks include ketoacidosis, acute kidney injury, and genitourinary infections 1, 4
• Discontinue in severe renal impairment 1
• Canagliflozin associated with increased amputation risk 1

GLP-1 Receptor Agonists

• Common gastrointestinal side effects (nausea, vomiting) typically diminish over time 1
• Require subcutaneous injection (except oral semaglutide) 1
• Do not combine with DPP-4 inhibitors as there is no additive benefit 1

Practical Implementation

Start with lifestyle modification concurrent with pharmacotherapy as diet and exercise remain foundational 1

• If A1C is 1.5-2.0% above target when initiating therapy without metformin, consider starting with combination therapy using two agents from different classes 1
• Reassess treatment efficacy every 3 months and intensify therapy if A1C targets are not met 1
• Continue the selected alternative agent long-term unless contraindications develop or intolerance occurs 1